Normal View Dyslexic View

Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer. A randomized clinical trial.

29 August 2023
Randomized clinical trials General
Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL et al, for the CANVAS Investigators.

JAMA 2023; 329: 1924-1933.

This study included 671 patients with cancer and a new episode of VTE. After six months, the risk of recurrent VTE was not inferior with oral anticoagulation (6.1per cent), compared to those receiving low molecular weight heparin (8.8 per cent). Bleeding complication rates were similar.

Comment: Reassuring, and easier for patients.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Info
Copied!